Clinical trial
Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With…
NCT00113789 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00113789 |
|---|---|
| Title | Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer |
| Official title | Randomized, Phase 2 Study of Pegfilgrastim Given on the Last Day of a Multi-Day Topotecan Regimen or the Day After in Subjects With Relapsed or Refractory Ovarian Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Other |
| Interventions | PI Discretion |
| Enrollment | 21 |
| Start date | Oct 1, 2003 |
| Primary completion | Apr 1, 2005 |
| Completion | Apr 1, 2005 |
| First posted | Jun 13, 2005 |
| Last update posted | Feb 13, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: